2023-03-16 16:50:48 ET
- Spruce Biosciences press release ( NASDAQ: SPRB ): FY GAAP EPS of -$1.96 beats by $0.05 .
- Cash, cash equivalents and investments as of December 31, 2022 were $79.1 million, excluding $53.6 million in gross proceeds from the February 2023 private placement and the $15.0 million upfront payment due to the company from Kaken.
- The company has a banking relationship with Silicon Valley Bank but did not experience any financial losses or operational impact from the recent failure of the bank.
For further details see:
Spruce Biosciences GAAP EPS of -$1.96 beats by $0.05